Amol Akhade: What’s the story for Day 2 of ESMO2024

Amol Akhade shared a post on X:

“So what’s the story for day 2 of ESMO24 ?
Keynote A18 shows OS benifit.

Pembrolizumab in CTRT for cervix.
HR 0.67 ( 0.5 to 0.90 )

82.6 % vs 74.8 % OS at 36 months.

OS Benifit seen across all the stages.
This should make it new SOC. ”

Source: Amol Akhade/X

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.